[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634003":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":25,"interventions":31,"overallOfficials":18,"centralContacts":36,"locations":42,"responsibleParty":60,"collaborators":18,"id":62,"slug":18,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":18,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":45,"whyStopped":18,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Zhujiang Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Major pathological response","Major pathological response (MPR) was defined as ≤10% residual viable tumor cells in the tumor bed on pathological examination of the resected specimen in enrolled patients who underwent surgery within approximately 1 week after completion of three cycles of neoadjuvant therapy with a PD-1\u002FPD-L1 inhibitor plus LR607 and platinum-based doublet chemotherapy (approximately 63 days).","Day 1 to 4 weeks",[14],{"measure":15,"description":16,"timeFrame":17},"Pathological Complete Response","Pathological complete response (pCR) was defined as no residual viable tumor cells in the resected primary lung tumor and all resected regional lymph nodes on pathological examination of the resected specimen in enrolled patients who underwent surgery within approximately 1 week after completion of three cycles of neoadjuvant therapy with a PD-1\u002FPD-L1 inhibitor plus LR607 and platinum-based doublet chemotherapy (approximately 63 days).","Day 1 to 4 Weeks",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"NA","SINGLE_GROUP","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":18},"NONE",[26],{"label":27,"type":28,"description":18,"interventionNames":29},"Probiotics combined with neoadjuvant chemoimmunotherapy","EXPERIMENTAL",[30],"Drug: Probiotics combined with neoadjuvant chemoimmunotherapy",[32],{"type":33,"name":27,"description":34,"armGroupLabels":35,"otherNames":18},"DRUG","This clinical study aims to enhance efficacy by using functional probiotics selected from a Chinese food-grade probiotic library in combination with neoadjuvant chemoimmunotherapy.",[27],[37],{"name":38,"role":39,"phone":40,"phoneExt":18,"email":41},"Xin Li","CONTACT","+8619878478083","1098353704@qq.com",[43],{"facility":44,"status":45,"city":46,"state":18,"zip":18,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Zhu Jiang Hospital of Southern Medical University","RECRUITING","Guangzhou","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56],{"name":57,"role":39,"phone":58,"phoneExt":18,"email":59},"Xiaolong He","18620071640","hxl2027315@smu.edu.cn",{"type":61,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100634003",false,"NCT07534033","Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer","Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Histologically confirmed newly diagnosed patients\n2. ECOG performance status 0-1\n3. Age ≥18 years\n4. Measurable lesions (RECIST v1.1)\n5. Organ function meeting the requirements for chemotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. Including active autoimmune diseases\n2. Recent use of immunosuppressants\n3. Interstitial lung disease\n4. Presence of other malignancies\n5. History of immunotherapy\n6. Active infection\n7. Pregnancy or drug allergies",true,"ALL","18 Years","80 Years",{"count":73,"type":74},46,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:\n\nCan LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment?\n\nParticipants will:\n\nTake LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions",[80,81,82,83],"NSCLC Diagnosed by Histology or Cytology","A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection","Overall Lung Function is Adequate for the Planned Lung Resection","AJCC is Classified as IB-IIIC",[85,86,87],"NSCLC","IB-IIIC stage","Resectable NSCLC","2026-04-13",{"date":90,"type":91},"2026-04-16","ACTUAL",{"date":93,"type":91},"2025-12-06",{"date":95,"type":74},"2027-12-23",{"name":5,"class":6},1]